Oramed Pharmaceuticals (ORMP)

Oramed Pharmaceuticals Stock Analysis & Ratings

ORMP Stock Chart & Stats

Day’s Range$4.22 - $4.79
52-Week Range$3.74 - $31.54
Previous Close$4.14
Average Volume (3M)694.05K
Market Cap$176.24M
P/E Ratio-5.9
Next EarningsJul 13, 2022
Next Dividend Ex-DateN/A
Dividend YieldN/A
Smart Score1
EPS (TTM)-0.77



P/E Ratio Range

The price to earnings ratio. This is used by investors to assess a stock’s market price relative to its earnings.


Risk Analysis

Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy

Product Monthly Users

Sorry, No Data Available
There is no website visitor data available for this stock.



What was Oramed Pharmaceuticals’s price range in the past 12 months?
Oramed Pharmaceuticals lowest stock price was $3.74 and its highest was $31.54 in the past 12 months.
    What is Oramed Pharmaceuticals’s market cap?
    Oramed Pharmaceuticals’s market cap is $176.24M.
      What is Oramed Pharmaceuticals’s price target?
      The average price target for Oramed Pharmaceuticals is $26.00. This is based on 2 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
      The highest analyst price target is $32.00 ,the lowest forecast is $20.00. The average price target represents 468.93% Increase from the current price of $4.57.
        What do analysts say about Oramed Pharmaceuticals?
        Oramed Pharmaceuticals’s analyst rating consensus is a ‘Moderate Buy. This is based on the ratings of 2 Wall Streets Analysts.
          When is Oramed Pharmaceuticals’s upcoming earnings report date?
          Oramed Pharmaceuticals’s upcoming earnings report date is Jul 13, 2022 which is in 58 days.
            How were Oramed Pharmaceuticals’s earnings last quarter?
            Oramed Pharmaceuticals released its earnings results on Jan 11, 2022. The company reported -$0.215 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.215.
              Is Oramed Pharmaceuticals overvalued?
              According to Wall Street analysts Oramed Pharmaceuticals’s price is currently Undervalued.
                Does Oramed Pharmaceuticals pay dividends?
                Oramed Pharmaceuticals does not currently pay dividends.
                What is Oramed Pharmaceuticals’s EPS estimate?
                Oramed Pharmaceuticals’s EPS estimate for its next earnings report is not yet available.
                How many shares outstanding does Oramed Pharmaceuticals have?
                Oramed Pharmaceuticals has 38,560,000 shares outstanding.
                  What happened to Oramed Pharmaceuticals’s price movement after its last earnings report?
                  Oramed Pharmaceuticals reported an EPS of -$0.215 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 0.166%.
                    Which hedge fund is a major shareholder of Oramed Pharmaceuticals?
                    Currently, no hedge funds are holding shares in ORMP


                    Oramed Pharmaceuticals Stock Analysis

                    Smart Score
                    Price Target
                    ▲(468.93% Upside)
                    Moderate Buy
                    The Oramed Pharmaceuticals stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                    Learn more about TipRanks Smart Score

                    Company Description

                    Oramed Pharmaceuticals

                    Oramed Pharmaceuticals, Inc. engages in the provision of oral delivery solutions for drugs delivered via injection. It focuses in the research and development of pharmaceutical solutions, including an oral insulin capsule to be used for the treatment of individuals with diabetes, and the use of orally ingestible capsules or pills for delivery of other polypeptides. The company was founded by Nadav Kidron and Miriam Kidron on April 12, 2002 and is headquartered in Jerusalem, Israel.

                    Similar Stocks
                    Price & Change
                    Novo Nordisk
                    Generex Biotechnology
                    Sanofi-Aventis Sa
                    vTv Therapeutics
                    Adocia SA

                    Popular Stocks

                    What's Included in PREMIUM?
                    Make informed decisions based on Top Analysts' activity
                    Know what industry insiders are buying
                    Get actionable alerts from top Wall Street Analysts
                    Find out before anyone else which stock is going to shoot up
                    Get powerful stock screeners & detailed portfolio analysis